AI assistant
Nautilus Biotechnology, Inc. — Director's Dealing 2021
Jun 9, 2021
34183_dirs_2021-06-09_e98b5c8a-79c5-4427-8030-0809b9439356.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Nautilus Biotechnology, Inc. (NAUT)
CIK: 0001808805
Period of Report: 2021-06-09
Reporting Person: Mowry Anna (CFO and Treasurer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.14 | 2030-12-03 | Common Stock (435368.0) | Direct |
Footnotes
F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, 13/49ths of the shares subject to the Option shall vest on the thirteen (13) month anniversary of the Vesting Commencement Date (as defined below), and one forty-ninth (1/49th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month).The Vesting Commencement Date is December 3, 2020.